PE20091628A1 - Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona - Google Patents

Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Info

Publication number
PE20091628A1
PE20091628A1 PE2009000395A PE2009000395A PE20091628A1 PE 20091628 A1 PE20091628 A1 PE 20091628A1 PE 2009000395 A PE2009000395 A PE 2009000395A PE 2009000395 A PE2009000395 A PE 2009000395A PE 20091628 A1 PE20091628 A1 PE 20091628A1
Authority
PE
Peru
Prior art keywords
benzimidazol
methylpiperazin
quinolin
fluoro
amino
Prior art date
Application number
PE2009000395A
Other languages
English (en)
Inventor
Danielle Giron
Philippe Piechon
Walter Hammerschmidt
Johanne Polasek
Andreas Schreiner
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091628A1 publication Critical patent/PE20091628A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA SAL CRISTALINA DE ACIDO LACTICO DE A) FORMA ANHIDRA II DE 4-AMINO-5-FLUORO-3-[5-(4-METILPIPERAZIN-1-IL)-1H-BENZIMIDAZOL-2-IL]QUINOLIN-2(1H)-ONA QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVOS EXPRESADOS EN GRADOS 2 TETA DE 8.2, 11.8, 12.9, 13.8, 14.7, 16.6, 18.5, 20.3 Y 23.5; Y B) FORMA HEMI-PENTAHIDRATADA DE 4-AMINO-5-FLUORO-3-[5-(4-METILPIPERAZIN-1-IL)-1H-BENZIMIDAZOL-2-IL]QUINOLIN-2(1H)-ONA QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVOS EXPRESADOS EN GRADOS 2 TETA DE 6.8, 9.3, 12.1, 12.7, 13.1, 13.4, 16.5, 17.3, 18.7, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHAS FORMAS CRISTALINAS LAS CUALES SON UTILES PARA EL TRATAMIENTO DEL CANCER DE PROSTATA, CANCER DE PANCREAS, SARCOMA, LINFOMA
PE2009000395A 2008-03-19 2009-03-17 Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona PE20091628A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19

Publications (1)

Publication Number Publication Date
PE20091628A1 true PE20091628A1 (es) 2009-11-19

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000395A PE20091628A1 (es) 2008-03-19 2009-03-17 Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Country Status (25)

Country Link
US (1) US8563556B2 (es)
EP (1) EP2257544B1 (es)
JP (1) JP2011515370A (es)
KR (1) KR20100137517A (es)
CN (1) CN101970425B (es)
AR (1) AR070924A1 (es)
AU (1) AU2009227003B2 (es)
BR (1) BRPI0909762A2 (es)
CA (1) CA2718076A1 (es)
CL (1) CL2009000651A1 (es)
CO (1) CO6321253A2 (es)
EC (1) ECSP10010555A (es)
HK (1) HK1147492A1 (es)
IL (1) IL208020A0 (es)
MA (1) MA32230B1 (es)
MX (1) MX2010010152A (es)
MY (1) MY150554A (es)
NZ (2) NZ600887A (es)
PE (1) PE20091628A1 (es)
PH (2) PH12012502569A1 (es)
RU (1) RU2497820C2 (es)
SG (1) SG188919A1 (es)
TW (1) TWI426072B (es)
WO (1) WO2009115562A2 (es)
ZA (1) ZA201006263B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2011128403A1 (en) 2010-04-16 2011-10-20 Novartis Ag Organic compound for use in the treatment of liver cancer
CN102834094B (zh) 2010-04-16 2015-05-06 诺华有限公司 有机化合物的组合产品及其制药用途
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
US20130345234A1 (en) 2011-03-17 2013-12-26 Humphrey Athelstan Roy Gardner Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
SG194445A1 (en) 2011-05-19 2013-12-30 Novartis Ag Method for treating adenoid cystic carcinoma
JP2014526506A (ja) 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2861377A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
IN2014DN10801A (es) 2012-07-11 2015-09-04 Novartis Ag
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SI3116909T1 (sl) 2014-03-14 2020-03-31 Novartis Ag Molekule protiteles na LAG-3 in njih uporaba
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317442B1 (en) 2000-09-11 2005-11-16 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
KR20060111520A (ko) * 2003-11-07 2006-10-27 카이론 코포레이션 Ｆｇｆｒ3의 억제 및 다발성 골수종의 치료
CA2556872C (en) * 2004-02-20 2015-05-12 Chiron Corporation Modulation of inflammatory and metastatic processes
EP1845990B1 (en) * 2005-01-27 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Treatment of metastasized tumors
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
AU2006320591B2 (en) * 2005-11-29 2010-06-03 Novartis Ag Formulations of quinolinones
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
IL208020A0 (en) 2010-12-30
KR20100137517A (ko) 2010-12-30
HK1147492A1 (en) 2011-08-12
WO2009115562A3 (en) 2009-11-26
MY150554A (en) 2014-01-30
CO6321253A2 (es) 2011-09-20
SG188919A1 (en) 2013-04-30
US8563556B2 (en) 2013-10-22
PH12012502569A1 (en) 2015-09-21
EP2257544B1 (en) 2014-12-03
TWI426072B (zh) 2014-02-11
CA2718076A1 (en) 2009-09-24
CN101970425B (zh) 2014-04-16
AR070924A1 (es) 2010-05-12
BRPI0909762A2 (pt) 2018-04-03
TW201000463A (en) 2010-01-01
MX2010010152A (es) 2010-10-25
US20110021536A1 (en) 2011-01-27
JP2011515370A (ja) 2011-05-19
CN101970425A (zh) 2011-02-09
AU2009227003A1 (en) 2009-09-24
CL2009000651A1 (es) 2010-07-19
ZA201006263B (en) 2011-05-25
MA32230B1 (fr) 2011-04-01
NZ587829A (en) 2012-08-31
NZ600887A (en) 2013-10-25
RU2010142396A (ru) 2012-04-27
PH12012502568A1 (en) 2014-10-27
AU2009227003B2 (en) 2013-03-14
EP2257544A2 (en) 2010-12-08
RU2497820C2 (ru) 2013-11-10
ECSP10010555A (es) 2010-11-30
WO2009115562A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
PE20091628A1 (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
CU20120169A7 (es) Compuestos pirimidinílicos como inhibidores de la cinasa atr
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
PH12016500024A1 (en) Bromodomain inhibitor
MX2015011955A (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
MX2015012431A (es) Pirrol amida como inhibidores.
MX2015012005A (es) Inhibidores de bromodominio.
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
PH12015501088A1 (en) Dimeric compounds
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX364649B (es) Composición antimicrobiana.
CL2014002181A1 (es) Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.
CA2927016C (en) Oral care composition
MX347858B (es) Composición antimicrobiana.
PH12015500185A1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
EA201591649A1 (ru) Составы с органическими соединениями
MX347389B (es) Composicion antimicrobiana.
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
PH12015500399A1 (en) Azaindolines
MX2015012386A (es) Inhibidores de la cinasa cdk9.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed